Form 4 Filing for Mary Thistle at Cullinan Therapeutics, Inc.

This filing details a Form 4 submission by Mary Thistle, a director at Cullinan Therapeutics, Inc. (CGEM). On June 16, 2026, Thistle was granted a stock option to purchase 25,319 shares of the company's Common Stock at an exercise price of $13.55 per share. The option is set to vest in full on the earlier of June 16, 2027, or the date of the company's next annual meeting, contingent upon Thistle's continued service as a director. The transaction code "A" indicates an acquisition of securities. Following this transaction, Thistle holds 25,319 shares of the underlying Common Stock upon exercise. The filing was signed on June 18, 2026, by Jacquelyn Sumer as Attorney-in-Fact.